Puerto Rico's healthcare system requires patients to navigate a fragmented network of physicians, health plans, specialty pharmacies and financial assistance programs. Much of the care is delivered through independent physician practices that lack the administrative resources needed to coordinate complex therapies. For patients facing cancer, rare diseases and other serious conditions, managing their illness while navigating this complex system can become overwhelming. Alivia Health simplifies the care journey with its integrated pharmaceutical care model. Its model connects patients, physicians, managed care organizations (MCOs) and pharmaceutical manufacturers in a coordinated network. Alivia provides specialty medications, oncology therapies, infusion services and home pharmacy solutions through its integrated model. Bringing traditionally separate services together reduces the administrative, financial and clinical barriers that delay treatment. Patients spend less time navigating the system and more time focusing on their health..

IFM Quality Services, a laboratory quality-assurance provider, once sent a laboratory a proficiency-testing sample containing a higher than expected level of the target bacterium. The agar showed the expected positive color reaction. However, the laboratory reported a negative result because the plate was overrun with target bacteria, making individual colonies indistinguishable. The laboratory had initially misinterpreted the results and did not investigate the unexpected finding, revealing a gap in their testing procedure. A subsequent review and update of the laboratory’s procedure produced a more robust test system, with lessons applicable to other analytical methods. The scenario underlines IFM’s deliberate approach to proficiency testing, using challenging samples to uncover weaknesses that routine testing may not reveal. The value of this approach extends beyond confirming the accuracy of a laboratory’s results. It provides insight into where its methods or result interpretation need strengthening..

NeoBiotechnologies sets a new benchmark in monoclonal antibody production as an original manufacturer delivering an extensive portfolio of over 10,000 expertly designed monospecific antibodies. In a crowded market full of resellers who rebrand products produced by a small contingent of manufacturers, NeoBiotechnologies stands apart. By controlling every step of production—development to rigorous validation—NeoBiotechnologies ensures a level of quality and reliability that no competitor can rival. This hands-on approach addresses a critical issue identified by the National Institutes of Health (NIH): nearly 70% of published research is irreproducible due to antibodies lacking monospecificity. Non-specific antibodies frequently bind to unintended targets, leading to flawed conclusions, wasted resources, and setbacks in research. Rigorous testing and validation allow NeoBiotechnologies to produce highly specific antibodies, reacting exclusively with their intended targets and consistently meeting quality benchmarks. This comprehensive dedication to precision ensures consistent results across applications, including solid tumor analysis, liquid biopsies, urine, and sputum samples—fully equipping researchers and diagnosticians with accurate, reproducible data that advances their work instead of precluding it. “With over 80% of our team dedicated to in-house testing, we ensure unmatched precision and reliability through rigorous development and characterization,” says Dr. Tandon, President and CEO. Widely known as “the MabMan”—the Monoclonal Antibody Man—for his groundbreaking contributions to the field, Dr. Tandon’s journey into monoclonal antibody technology began in the 1980s, when the field was still in its infancy. While conducting breast cancer research at the University of Texas Health Science Center, he identified a critical inefficiency: researchers were often unknowingly purchasing identical antibodies from different companies, rebranded and sold at inflated prices. This practice drained research budgets and wasted valuable time that should have been directed toward advancing discovery. Determined to meet this challenge, he transitioned from academia to establish NeoMarkers, a company dedicated to providing highquality antibodies to the scientific community. Building on this foundation, he launched NeoBiotechnologies in 2013 with a mission to redefine the monoclonal antibody field through uncompromising quality and cutting-edge innovation. Today, NeoBiotechnologies is recognized globally for its contributions to research, diagnostics, and therapeutic applications across oncology, immunology, neuroscience, and metabolism..